Recursion CEO sells 23,588 shares under 10b5-1 plan

Recursion Pharmaceuticals CEO and President Najat Khan reported an open-market sale of 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share.

Rhea-AI Filing Summary

Recursion Pharmaceuticals CEO and President Najat Khan reported an open-market sale of 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025.

After this sale, Khan directly holds 2,175,796 shares, indicating she retains a substantial ownership stake in the company while taking limited liquidity through this planned transaction.

Insider Trade Summary 10b5-1

Net Seller: 23,588 shares

Net Sell 1 txn

Insider Khan Najat

Role CEO and President

Sold 23,588 shs ($84K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	23,588	$3.5806	$84K

Holdings After Transaction: Class A Common Stock — 2,175,796 shares (Direct)

Footnotes (2)

1. F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $3.56 to $3.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 23,588 shares Sale price: $3.5806 per share Post-transaction holdings: 2,175,796 shares +3 more

6 metrics

Shares sold 23,588 shares Open-market sale of Class A Common Stock

Sale price $3.5806 per share Weighted average sale price

Post-transaction holdings 2,175,796 shares Shares directly held after sale

Transaction code S Open-market or private sale of non-derivative security

Plan adoption date September 22, 2025 Rule 10b5-1 trading plan adoption

Price range $3.56–$3.62 per share Multiple trades within this range

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Class A Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RXRX CEO Najat Khan report?

Najat Khan reported an open-market sale of 23,588 shares of Recursion Pharmaceuticals Class A Common Stock at a weighted average price of $3.5806 per share. Following the transaction, she directly holds 2,175,796 shares in the company.

Was the RXRX CEO stock sale under a Rule 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 trading plan adopted on September 22, 2025. Such plans pre-schedule trades, making the timing more routine and reducing the significance of short-term market conditions for this transaction.

How many RXRX shares does CEO Najat Khan own after this sale?

After selling 23,588 shares, Najat Khan directly holds 2,175,796 shares of Recursion Pharmaceuticals Class A Common Stock. This indicates she maintains a large ongoing equity position despite the recent open-market sale reported in the Form 4.

What price range did the RXRX CEO’s share sale occur at?

The transaction was executed in multiple trades at prices ranging from $3.56 to $3.62 per share. The reported $3.5806 figure represents the weighted average sale price across all trades included in this Form 4 transaction.

Is the RXRX CEO’s reported transaction a buy or sell?

The transaction is a sale. Najat Khan executed an open-market sale of 23,588 shares of Recursion Pharmaceuticals Class A Common Stock, as reflected by transaction code "S" and the sell designation in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/05/2026		S(1)		23,588	D	$3.5806(2)	2,175,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.

2. This transaction was executed in multiple trades at prices ranging from $3.56 to $3.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)